<DOC>
	<DOCNO>NCT00066196</DOCNO>
	<brief_summary>The primary objective study : - To explore antitumor activity MEDI-522 ± DTIC patient metastatic melanoma . - To determine safety MEDI-522 ± DTIC patient population .</brief_summary>
	<brief_title>Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma</brief_title>
	<detailed_description>This Phase II , randomize , open-label , two-arm , multicenter study MEDI 522 ± DTIC previously untreated ( adjuvant immunotherapy ) patient Stage IV metastatic melanoma ( AJCC stag ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Inclusion Patients must meet follow criterion time randomization : Histologically confirm , unresectable , Stage IV metastatic melanoma ( AJCC stag ) , least one measurable lesion define least one lesion accurately measure least one dimension ( long diameter record ) ³ 20 mm conventional technique ³ 10 mm spiral compute tomography ( CT ) scan ; Adult men woman least 18 year age time randomization ; Women reproductive potential ( define &lt; 1 year postmenopausal ) must negative serum β human chorionic gonadotropin ( βhCG ) pregnancy test within 3 day prior randomization ; men woman reproductive potential must agree practice effective method avoid pregnancy ( include oral implanted contraceptive , intrauterine device ( IUD ) , condom , diaphragm spermicide , cervical cap , abstinence , sterile sexual partner ) time inform consent sign , must agree continue use precaution receive MEDI522 30 day final dose MEDI522 ; Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 ; Life expectancy least 16 week ; WBC ≥ 3,000/mm3 , absolute neutrophil count ( ANC ) ≥ 1,500/mm3 , platelet count ≥ 100,000/mm3 ; Bilirubin ≤ 1.5 mg/dL , aspartate transaminase ( AST ) /alanine transaminase ( ALT ) ≤ 3 time upper limit normal ( ULN ) , serum creatinine ≤ 1.5 mg/dL , alkaline phosphatase ≤ 3.0 time ULN prothrombin time ( PT ) /partial thromboplastin time ( PTT ) international normalize ratio ( INR ) within normal range ; Patients prior treatment adjuvant immunotherapy eligible study randomization provide therapy end least 4 week prior randomization ; Patients prior surgery eligible least 4 week pass since surgery ; All toxicity relate prior adjuvant therapy must resolve surgical wound must heal ; Written inform consent HIPAA authorization obtain patient prior receipt study medication begin study procedure . Exclusion Patients must none following time randomization : Pregnancy nursing ; Prior therapy metastatic melanoma include chemotherapy , radiotherapy , hormonal therapy , biologics ; Any concurrent chemotherapy , radiotherapy , immunotherapy , biologic hormonal therapy treatment cancer ; Current plan participation ( day randomization 30 day last dose MEDI522 ) research protocol investigational agent therapy may administer ; Received investigational agent within 4 week prior randomization ; Known brain metastasis primary brain tumor , ocular melanoma , symptomatic pleural effusion ascites require paracentesis ; History prior malignancy within past 5 year nonmelanomatous skin cancer control , carcinoma situ cervix , T1a b prostate cancer note incidentally transurethral resection prostate ( TURP ) prostatespecific antigen ( PSA ) value within normal limit since TURP , superficial bladder cancer ; History pulmonary embolus . Any history evidence pulmonary embolism thrombophlebitis ( include deep vein thrombosis ) require anticoagulant therapy ( i.e. , warfarin heparin ) . Currently require therapeutic anticoagulation . Any evidence hematemesis , melena , hematochezia , gross hematuria ; History presence bleeding diatheses ; Elective surgery plan study period 30 day last dose MEDI522 . History hypersensitivity previously administer monoclonal antibody . History hypersensitivity DTIC ; History immunodeficiency ; Known human immunodeficiency virus ( HIV ) know active viral hepatic infection ; A prior myocardial infarction angina , uncontrolled/refractory hypertension within 6 month prior randomization ; A prior stroke transient ischemic attack within past 6 month ; An active infection require systemic antiinfective therapy ; Prior treatment MEDI522 MEDI523 ; A general medical psychological condition behavior , include substance dependence abuse , opinion investigator , might permit patient complete study sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>